SynBioBeta Speaker
Alexandre Zanghellini
Arzeda
Co-founder & CEO
Alexandre Zanghellini co-founded Arzeda and leads the team as CEO and Vice President, Research. Alexandre is an internationally recognized protein design expert and was the early developer of Arzeda’s protein design software Archytas™ for enzyme design, as well as Arzeda’s metabolic pathway design software Scylax™. Before Arzeda, Alexandre led bioinformatics at Cellectis (NASDAQ: CLLS), a publicly traded protein engineering and gene editing company.Alexandre strongly believes the convergence of big compute, machine learning, DNA synthesis and lab automation represent an inflexion point in human history, and that the rationale design of new proteins will play a key role in solving some of humanity’s biggest societal challenges – from improving human well-being to combating climate change. Alexandre holds a Ph.D. in Biochemistry from University of Washington, a M.S. in Computer Science (Artificial Intelligence) and B.S. in Applied Mathematics, both from University of Paris, and a M.Eng. from ENSTA/ParisTech.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Alexandre
This Year
•
-
Tools & Tech
From AI protein design to real-world commercial impact: powering the next wave of everyday products
For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.
Get a Ticket
•
-
Tools & Tech
From AI protein design to real-world commercial impact: powering the next wave of everyday products
For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
